Keywords
juvenile dermatomyositis
systemic sclerosis
child
How to Cite
Abstract
Introduction: Pulmonary arterial hypertension may be secondary associated with connective tissue diseases. Among these diseases, systemic sclerosis and juvenile dermatomyositis predominate.
Materiales and Methods: A retrospective, descriptive and cross-sectional study was ca- rried out. All patients with a diagnosis of juvenile dermatomyositis and systemic sclerosis who attended our hospital were included. Pulmonary arterial pressure levels were subse- quently verified by echocardiography.
Results: 58 patients were included, of which only 17 patients had a diagnostic echocardio- graphy. Among them, two patients presented pulmonary arterial hypertension.
Conlcusión: Timely detection of pulmonary arterial hypertension in connective tissue di- seases is essential. It is generally asymptomatic. It is necessary to adhere to the inter- national protocol that suggests performing echocardiography in all patients with juvenile dermatomyositis and systemic sclerosis.
References
(1) Faqih SA, Noto-Kadou-Kaza B, Abouamrane LM, Mtiou N, El Khayat S, Zamd M, et al. Pulmonary hypertension: prevalence and risk factors. Int J Cardiol Heart Vasc [Internet]. 2016;11:87–9. Disponible en: http://dx.doi.org/10.1016/j.ijcha.2016.05.012
(2) Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treat- ment of pulmonary hypertension. Eur Heart J. 2022 Oct 11; 43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
(3) Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med [Internet]. 2009;179(7):615–21. Disponible en: http://dx.doi.org/10.1164/rccm.200811-1691oc
(4) Pérez-Olivares Delgado Carmen, Aurtenetxe Pérez, Águeda, Escribano Subías Pilar. Hipertensión arterial pulmonar:: progresión, pronóstico e impacto. Insuf. card. [Internet]. 2019 Mar [citado 2023 Oct 04] ; 14( Suppl 1 ): 1-(7) Disponible en: http://www.scielo.org.ar/ scielo.php?script=sci_arttext&pid=S185238622019000200001 &lng=es.
(5) Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) [Internet]. 2013;92(1):25–41. Disponible en: http://dx.doi.org/10.1097/md.0b013e31827f264d
(6) Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: A systematic literature review. Semin Arthritis Rheum [Internet]. 2008;37(4):223–35. Disponible en: http://dx.doi.org/10.1016/j.semarthrit.2007.05.003
(7) Masi AT, Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum [Internet]. 1980;23(5):581– 90. Disponible en: http://dx.doi.org/10.1002/art.1780230510)
(8) Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA, Lehman TJA, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum [Internet]. 2007;57(2):203–12. Disponible en: http:// dx.doi.org/10.1002/art.22551
(9) van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis [Internet]. 2013;72(11):1747–55. Disponible en: http://dx.doi.org/10.1136/ annrheumdis-2013-204424
(10) Bohan A, Peter JB. Polymyositis and dermatomyositis: (First of two parts). N Engl J Med [Internet]. 1975;292(7):344–7. Disponible en: http://dx.doi.org/10.1056/nejm197502132920706
(11) Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M de, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis [Internet]. 2017;76(12):1955–64. Disponible en: http://dx.doi.org/10.1136/annrheumdis-2017-211468
(12) Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum [Internet]. 2014;44(1):55–62. Disponible en http://dx.doi.org/10.1016/j.semarthrit.2014.03.002
(13) Robb-Smith AH, Dowling GB. Discussion on the collagen vascular diseases. Proc R Soc Med. 1952 Dec;45(12):811-20.
(14) Trapani S, Camiciottoli G, Vierucci A, Pistolesi M, Falcini F. Pulmonary involvement in juvenile dermatomyositis: a two‐year longitudinal study. Rheumatology (Oxford) [Internet]. 2001; 40(2):216–20. Disponible en: http://dx.doi.org/10.1093/rheumatology/ 40.2.216
(15) Treviño AVV. Dermatomiositis juvenil, características clínicas y factores predictores de respuesta a primera línea de tratamiento en pacientes mexicanos [Internet]. [Ciudad de México, México]: Universidad nacional autónoma de México; 2016. Disponible en: https://repositorio.unam.mx/contenidos/dermatomiositis-juvenil- caracteristicas-clinicas-y-factores-predictores-de-respuesta-a- primera-linea-de-tratamien-399888?c=kGDqA2&d=false&q=dise% C3%B1o_._del_._esquema_._de_._puesta_._a_._tierra_._en_._clini cas&i=5&v=1&t=search_1&as=0
(16) Allenbach Y, Benveniste O. Diagnostic utility of auto-antibodies in inflammatory muscle diseases. J Neuromuscul Dis [Internet]. 2015;2(1):13–25. Disponible en: http://dx.doi.org/10.3233/ jnd-140054
(17) Rubio-Rivas M, Homs NA, Cuartero D, Corbella X. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. Autoimmun Rev [Internet]. 2021;20(1):102713. Disponible en: http://dx.doi.org/ 10.1016/j.autrev.2020.102713
(18) Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa- Garriga G, Campillo-Grau M, Ramos-Casals M, et al. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death. Medicine (Baltimore) [Internet]. 2015; 94(43):e1728. Disponible en: http://dx.doi.org/10.1097/md. 0000000000001728
(19) Methia N, Latreche S, Benkhedda S. Frequency of PAH in scleroderma Algerian patients. Arch Cardiovasc Dis Suppl [Internet]. 2016;8(1):62. Disponible en: http://dx.doi.org/10.1016/s18786480 (16)30184-7
(20) Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumato [Internet]. 2010;37(11):2290–8. Disponible en: http://dx.doi. org/10.3899/jrheum.100245
(21) Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis- associated pulmonary hypertension: A systematic review and meta- analysis: Survival and prognosis in SSc-associated pulmonary hypertension. Arthritis Rheum [Internet]. 2013;65(9):2412–23. Disponible en: http://dx.doi.org/10.1002/art.38029
(22) Apitz C, Girschick H. Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovasc Diagn Ther [Internet]. 2021;11(4):1137–43. Disponible en: http://dx.doi.org/10.21037/cdt- 20-901
(23) Hachulla E, Launay D, Boucly A, Mouthon L, de Groote P, Cottin V, et al. Survival improved in patients aged ≤ 70 years with systemic sclerosis-associated pulmonary arterial hypertension during the period 2006 to 2017 in France. Chest [Internet]. 2020;157(4):945– 54. Disponible en: http://dx.doi.org/10.1016/j.chest.2019.10.045
(24) Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) [Internet]. 2012;51(6):1017–(25) Disponible en: http:// dx.doi.org/10.1093/rheumatology/ker269